410 related articles for article (PubMed ID: 16740767)
1. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
2. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
[TBL] [Abstract][Full Text] [Related]
3. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
[TBL] [Abstract][Full Text] [Related]
6. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
8. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice.
Okamoto K; Neureiter D; Alinger B; Meissnitzer M; Sass G; Schmitz V; Di Fazio P; Wissniowski T; Gahr S; Hohenstein B; Kaufmann B; Schlösser A; Haus U; Hahn EG; Herold C; Ocker M
Int J Oncol; 2008 Oct; 33(4):733-42. PubMed ID: 18813786
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
[TBL] [Abstract][Full Text] [Related]
10. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
15. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
17. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
